Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.68 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.57 |
| ▸ | KIF11 | P52732 | 3/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7506839 | 0.94 | PTGS2 (0.72) | PTGS2AKR1C3KIF11 | |
| SCHEMBL7990329 | 0.88 | PTGS2 (0.57) | PTGS2AKR1C3KIF11CYP11B1CYP11B2 | |
| SCHEMBL19322102 | 0.87 | PTGS2 (0.55) | PTGS2AKR1C3KIF11CYP11B1CYP11B2 | |
| SCHEMBL7802254 | 0.87 | AKR1C3 (0.62) | PTGS2AKR1C3CYP11B1CYP11B2 | |
| SCHEMBL6728363 | 0.85 | PTGS2 (0.68) | PTGS2KIF11 | |
| SCHEMBL28359568 | 0.84 | PTGS2 (0.51) | PTGS2AKR1C3KIF11ENPP2 | |
| SCHEMBL8974375 | 0.82 | PTGS2 (0.63) | PTGS2AKR1C3KIF11 | |
| SCHEMBL4004148 | 0.82 | CA12 (0.72) | AKR1C3CA1CA2 | |
| SCHEMBL215443 | 0.82 | PTGS2 (1.00) | PTGS2 | |
| SCHEMBL25607230 | 0.82 | PTGS2 (0.50) | PTGS2AKR1C3KIF11ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12478680-B2 | Hydrogels with biodegradable crosslinking | PROLYNX LLC (US) | 2025-11-25 | — | — | US | disclosed |
| CN-119390625-A | Preparation method of 1- (aryl sulfonyl) bicyclo [1.1.0] butane compound | 苏州百灵威超精细材料有限公司 | 2025-02-07 | — | — | CN | disclosed |
| WO-2024117595-A1 | ORGANIC ELECTRIC ELEMENT COMPRISING METAL PATTERNING LAYER AND ELECTRONIC DEVICE THEREOF | 덕산네오룩스 주식회사 | 2024-06-06 | — | — | WO | disclosed |
| EP-4313154-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | OD Therapeutics Limited (HK) | 2024-02-07 | — | — | EP | disclosed |
| CN-117355337-A | Protein-macromolecule conjugates and methods of use thereof | 奥迪曼药业科技有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20230135347-A1 | HYDROGELS WITH BIODEGRADABLE CROSSLINKING | PROLYNX LLC (US) | 2023-05-04 | — | — | US | disclosed |
| CN-115842164-A | Electrolyte solution, use, lithium ion battery, battery module, and battery pack | 宁德时代新能源科技股份有限公司 | 2023-03-24 | — | — | CN | disclosed |
| US-20220401561-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | AJ SCIENCES (YIXING) CO., LTD (CN) | 2022-12-22 | — | — | US | disclosed |
| WO-2022212362-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2022-10-06 | — | — | WO | disclosed |
| US-11454861-B2 | Hydrogels with biodegradable crosslinking | PROLYNX LLC (US) | 2022-09-27 | — | — | US | disclosed |
| WO-2004103998-A1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | WO | disclosed |
| US-20040132695-A1 | 24-Sulfur-substituted analogs of 1 alpha, 25-dihydroxy vitamin D3 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-07-08 | — | — | US | disclosed |
| EP-1419143-A1 | 24-SULFUR-SUBSTITUTED ANALOGS OF 1ALPHA,25-DIHYDROXY VITAMIN D3 | JOHNS HOPKINS UNIVERSITY (US) | 2004-05-19 | — | — | EP | disclosed |
| EP-1149094-B1 | 4-(AMINOALKOXY)BENZOFURANS AS N-MYRISTOYLTRANSFERASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2004-04-21 | — | — | EP | disclosed |
| US-20030149005-A1 | 24-sulfur-substituted analogs of 1alpha, 25-dihydroxy vitamin D3 | Opko IP Holdings II, Inc. (KY) | 2003-08-07 | — | — | US | disclosed |
| WO-2003018545-A1 | 24-SULFUR-SUBSTITUTED ANALOGS OF 1Α,25-DIHYDROXY VITAMIN D¿3? | JOHNS HOPKINS UNIVERSITY (US) | 2003-03-06 | — | — | WO | disclosed |
| US-6376491-B1 | BENZOFURAN DERIVATIVES FOR TREATMENT OR PREVENTION OF MYCOSIS IN MAMMALS | BASILEA PHARMACEUTICA AG (CH) | 2002-04-23 | — | — | US | disclosed |
| EP-1149094-A2 | 4-(AMINOALKOXY)BENZOFURANS AS N-MYRISTOYLTRANSFERASE INHIBITORS | Basilea Pharmaceutica AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| CN-1261876-A | N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases | ABBOTT LAB (US) | 2000-08-02 | — | — | CN | disclosed |
| WO-2000037464-A2 | 4-(AMINOALKOXY)BENZOFURANS AS N-MYRISTOYLTRANSFERASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149005-A1 | 24-sulfur-substituted analogs of 1alpha, 25-dihydroxy vitamin D3 | CYP24A1, CYP2R1, CYP27B1 | PTGS2 1632/4885AKR1C3 71/4885KIF11 3766/4885 |
| US-20230135347-A1 | HYDROGELS WITH BIODEGRADABLE CROSSLINKING | IDUA, APEH, GUSB | PTGS2 306/4885AKR1C3 2113/4885KIF11 3027/4885 |
| US-11454861-B2 | Hydrogels with biodegradable crosslinking | IDUA, APEH, GUSB | PTGS2 306/4885AKR1C3 2113/4885KIF11 3027/4885 |
| US-20040132695-A1 | 24-Sulfur-substituted analogs of 1 alpha, 25-dihydroxy vitamin D3 | CYP24A1, CYP2R1, CYP27B1 | PTGS2 1675/4885AKR1C3 79/4885KIF11 3418/4885 |
| US-12478680-B2 | Hydrogels with biodegradable crosslinking | IDUA, APEH, GUSB | PTGS2 306/4885AKR1C3 2113/4885KIF11 3027/4885 |
| US-20220401561-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | CD44, SSB, DNPEP | PTGS2 4247/4885AKR1C3 4494/4885KIF11 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.